From Bench to Babies - Drug Development for Male Subfertility.

Area of Science:

• Reproductive Medicine
• Pharmacology
• Drug Discovery

Background:

• Male infertility impacts over 50 million couples globally, with male factors contributing to half of cases.
• Current treatment options for male subfertility are scarce, primarily limited to assisted reproductive technologies like IVF and ICSI.
• Existing empirical treatments show variable effects on sperm function, with unclear benefits for actual fertility.

Purpose of the Study:

• To review current unlicensed and empirical treatments for male subfertility.
• To explore limitations in traditional drug discovery for male subfertility treatments.
• To highlight novel methods for accelerating and improving drug discovery efficiency in this field.

Main Methods:

• Review of existing literature on male subfertility treatments and drug discovery approaches.
• Analysis of challenges in identifying therapeutic targets due to limited understanding of sperm function.
• Examination of innovative drug discovery strategies such as high-throughput screening, combinatorial chemistry, and drug repurposing.

Main Results:

• Current empirical treatments offer limited and inconsistent benefits for male fertility.
• Traditional drug discovery is resource-intensive, time-consuming, and has a high failure rate, especially for male subfertility.
• Novel methods like high-throughput screening and drug repurposing can significantly enhance drug development efficiency and reduce costs.

Conclusions:

• There is a critical need for effective treatments for male subfertility.
• Advancements in drug discovery methodologies are essential to overcome current limitations.
• Innovative strategies hold significant potential to accelerate the development of much-needed therapies for subfertile men.